
Opinion|Videos|January 27, 2025
Assessing Symptoms, Treatment Decision-Making, and Monitoring
Panelists discuss when to adjust the dosage of current therapies like sertraline vs considering alternative treatments and the factors that guide these decisions, as well as whether treatments with rapid onset, such as zuranolone capsules or brexanolone intravenous (IV) infusion, would be appropriate for cases like Sarah’s, and what factors would influence the choice between these options.
Advertisement
Episodes in this series

Advertisement
Related to this article

Lisa Harding, MD, says ECT, ketamine, TMS, and VNS can work, but evidence on what comes after acute response remains thin.

Why D2 blockade alone falls short in schizophrenia, and what neurotransmitter, genetic and neuroimaging research means for treatment-resistant patients.

Discover expanded psychiatry coverage with new podcasts, interactive digital issues, and event reporting—we are your always-on media hub delivering fresh insights year-round.

GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.

Miss Golden Corner 2026 discusses the South Carolina campus naloxone law she helped start and her push to reduce addiction stigma in rural communities.

Explore the urgent legal, ethical, and clinical challenges in emergency psychiatry, share cases and tips, and contribute to Psychiatric Times’ November series.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Ozempic Dilemma: Promises and Pitfalls in Psychiatry
2
Schizophrenia: A Telltale of the Brain’s Complexity
3
Talking With Titans: Sheldon Preskorn, MD, on the Evolution of Psychopharmacology
4
Podcast: Interventional Psychiatry and the Challenge of Difficult-to-Treat Depression
5



